HTG Molecular Diagnostics Inc (NASDAQ:HTGM) fell 6.5% during trading on Monday . The company traded as low as $4.31 and last traded at $4.35. 1,285,272 shares changed hands during trading, an increase of 15% from the average session volume of 1,119,135 shares. The stock had previously closed at $4.65.

A number of research firms recently commented on HTGM. ValuEngine lowered shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Thursday, July 19th. HC Wainwright set a $7.00 price objective on shares of HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Tuesday, May 22nd. Finally, Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research report on Tuesday, August 14th. Five equities research analysts have rated the stock with a buy rating, HTG Molecular Diagnostics presently has an average rating of “Buy” and a consensus price target of $6.00.

The company has a current ratio of 9.50, a quick ratio of 9.29 and a debt-to-equity ratio of 0.35. The stock has a market cap of $132.16 million, a PE ratio of -2.43 and a beta of 1.77.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings data on Thursday, August 9th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.05. The business had revenue of $4.91 million for the quarter, compared to the consensus estimate of $5.30 million. HTG Molecular Diagnostics had a negative net margin of 81.10% and a negative return on equity of 132.67%. analysts anticipate that HTG Molecular Diagnostics Inc will post -0.71 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Spark Investment Management LLC purchased a new position in HTG Molecular Diagnostics during the 2nd quarter valued at $663,000. Stonepine Capital Management LLC purchased a new position in HTG Molecular Diagnostics during the 2nd quarter valued at $5,506,000. EAM Global Investors LLC purchased a new position in HTG Molecular Diagnostics during the 1st quarter valued at $684,000. Stifel Financial Corp purchased a new stake in shares of HTG Molecular Diagnostics in the 1st quarter worth about $343,000. Finally, Northern Trust Corp purchased a new stake in shares of HTG Molecular Diagnostics in the 1st quarter worth about $189,000. 49.17% of the stock is currently owned by institutional investors and hedge funds.

About HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.

Featured Story: Trading Strategy Methods for Individual Investors

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.